{"id":64157,"date":"2026-06-15T11:46:13","date_gmt":"2026-06-15T02:46:13","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4884-20260615-01_wp_basic\/"},"modified":"2026-07-12T11:57:07","modified_gmt":"2026-07-12T02:57:07","slug":"4884-20260615-01_wp_basic","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/","title":{"rendered":"Announcement of Initiation of Joint Research with Keio University on Acute Phase Protein Biomarkers for Predicting Natural Recovery and Assessing Treatment Efficacy in Spinal Cord Injury"},"content":{"rendered":"","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Kringle Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-15","jir_source_link":"[Placeholder]","jir_short_summary":"Entered into a joint research agreement with Keio University on acute-phase protein biomarkers for spinal cord injury prognosis and treatment effect evaluation. Continued preparations for a Phase III add-on clinical trial of the HGF formulation KP-100IT and advancing North American expansion. While the direct impact on performance is expected to be minor, research results are anticipated to contribute to the sophistication of clinical trial analysis and optimization of treatment strategies.","jir_summary":"### Key points of the news\nKringle Pharma has entered into a joint research agreement with Keio University School of Medicine to advance the analysis and evaluation of acute-phase protein biomarkers used to predict natural recovery after spinal cord injury and to assess treatment effects. We will continue domestic development and North American expansion of the HGF protein drug and prepare for the Phase III add-on clinical trial. The direct impact on performance is expected to be minimal.\n\n### Outlook and impact on investors\nThrough the joint research, the precision of clinical trial data analysis is expected to improve and spinal cord injury acute phase treatment strategies may be optimized. In the long term, it is anticipated that there will be knowledge gains that contribute to expanding the clinical application of HGF formulations and to the approvals processes domestically and internationally. However, as of now, the direct contribution to financials is limited, so short-term reinvestment effects are unclear.","jir_financial_highlights":"Revenue: Unknown\nNet income: Unknown","jir_category":"Partnerships & M&A","jir_hashtags":"#KringlePharma, #JointResearch, #Bioventure, #SpinalCordInjury","jir_key_figures":"Conclusion of joint research agreement (with Keio University)\nPreparation for Phase III add-on clinical trial domestically\nPreparation for North American expansion","jir_meta_title":"\u3010Kringle Pharma\u3011Notice of Joint Research with Keio University \uff5c June 2026","jir_meta_description":"Kringle Pharma signs a joint research agreement with Keio University to advance biomarker analysis and treatment effect evaluation for acute-phase spinal cord injury. Continuing preparations for Phase III add-on clinical trial of KP-100IT and North American expansion. Anticipated minor financial impact.","jir_og_title":"\u3010Kringle Pharma\u3011Notice of Joint Research Initiation \uff5c June 2026","jir_og_description":"Initiating spinal cord injury biomarker research with Keio University. Advancing clinical trial preparations domestically and internationally and North American expansion. Financial impact expected to be minor.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60826,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-64157","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Announcement of Initiation of Joint Research with Keio University on Acute Phase Protein Biomarkers for Predicting Natural Recovery and Assessing Treatment Efficacy in Spinal Cord Injury - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/\",\"name\":\"Announcement of Initiation of Joint Research with Keio University on Acute Phase Protein Biomarkers for Predicting Natural Recovery and Assessing Treatment Efficacy in Spinal Cord Injury - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-15T02:46:13+00:00\",\"dateModified\":\"2026-07-12T02:57:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Announcement of Initiation of Joint Research with Keio University on Acute Phase Protein Biomarkers for Predicting Natural Recovery and Assessing Treatment Efficacy in Spinal Cord Injury\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Announcement of Initiation of Joint Research with Keio University on Acute Phase Protein Biomarkers for Predicting Natural Recovery and Assessing Treatment Efficacy in Spinal Cord Injury - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/","url":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/","name":"Announcement of Initiation of Joint Research with Keio University on Acute Phase Protein Biomarkers for Predicting Natural Recovery and Assessing Treatment Efficacy in Spinal Cord Injury - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-15T02:46:13+00:00","dateModified":"2026-07-12T02:57:07+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20260615-01_wp_basic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Announcement of Initiation of Joint Research with Keio University on Acute Phase Protein Biomarkers for Predicting Natural Recovery and Assessing Treatment Efficacy in Spinal Cord Injury"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"60826","title":"\u30af\u30ea\u30f3\u30b0\u30eb\u30d5\u30a1\u30fc\u30de(\u682a)","ticker":"4884"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/64157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=64157"}],"version-history":[{"count":1,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/64157\/revisions"}],"predecessor-version":[{"id":79150,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/64157\/revisions\/79150"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=64157"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=64157"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=64157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}